Literature DB >> 8885698

Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists.

R A Coleman1, M Johnson, A T Nials, C J Vardey.   

Abstract

The four beta 2-adrenoceptor agonists, clenbuterol, bambuterol, formoterol and salmeterol, are all long-acting bronchodilators, that have distinct mechanisms for their extended durations of action. Various theories have been put forward in an attempt to explain these mechanisms. In this respect, there is strong evidence for the existence of specific additional binding sites (exosites) for salmeterol and related compounds, and that exosites exist on non-ligand recognition regions of the beta 2-adrenoceptor protein. Here, Robert Coleman and colleagues compare and contrast the profiles of action of these long-acting beta 2-adrenoceptor agonists, particularly as they relate to the role of exosites.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885698

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  17 in total

1.  Do fluorescent drugs show you more than you wanted to know?

Authors:  J C McGrath; C J Daly
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

Review 2.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 5.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 6.  On the mechanism of the persistent action of salmeterol: what is the current position?

Authors:  R A Coleman
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

7.  'Partial' competition of heterobivalent ligand binding may be mistaken for allosteric interactions: a comparison of different target interaction models.

Authors:  Georges Vauquelin; David Hall; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

Review 8.  Link between a high k on for drug binding and a fast clinical action: to be or not to be?

Authors:  Georges Vauquelin
Journal:  Medchemcomm       Date:  2018-08-16       Impact factor: 3.597

Review 9.  Clinical pharmacokinetics of salmeterol.

Authors:  Mario Cazzola; Renato Testi; Maria Gabriella Matera
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol.

Authors:  Anne-Marie Scola; Lee K Chong; S Kim Suvarna; Russell Chess-Williams; Peter T Peachell
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.